Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 2 (ICF2) Cell Models for Research

Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 2 (ICF2) is an ultra-rare autosomal recessive disorder. The exact prevalence is unknown, but fewer than 50 cases have been reported worldwide. ICF2 is characterized by severe immunodeficiency, centromeric instability, and facial anomalies. Patients typically present in infancy with recurrent infections, and many die in childhood. The syndrome is caused by mutations in the ZBTB24 gene, which plays a critical role in DNA methylation and chromatin organization. Early diagnosis is challenging due to phenotypic variability, and there is no cure. Management focuses on infection prophylaxis and immunoglobulin replacement. The disease serves as a model for understanding epigenetic regulation of immune function and centromere stability.

ICF2 is an excellent model for studying the interplay between epigenetics and immunity. The disease is monogenic, making it amenable to gene editing. Key research questions include: How does ZBTB24 regulate DNA methylation at centromeric regions? What are the downstream targets of ZBTB24 in immune cells? How do mutations in ZBTB24 lead to centromeric instability? Public datasets, such as those from the International ICF Registry, provide clinical and genetic data. Gene-edited cell models, such as ZBTB24 knockout cell lines, are essential for mechanistic studies and drug development.

ICF2 is primarily caused by loss-of-function mutations in ZBTB24, which encodes a zinc-finger protein involved in transcriptional regulation. The major pathways affected include:

• • DNA methylation maintenance: ZBTB24 interacts with the chromatin remodeling complex and is required for maintaining DNA methylation at centromeric repeats.
• • Immune cell development: ZBTB24 is highly expressed in B cells and T cells, and its loss leads to impaired lymphocyte maturation and function.
• • Centromere stability: Hypomethylation of centromeric regions leads to chromosome instability and abnormal nuclear morphology.

These pathways are interconnected, and their disruption contributes to the clinical phenotype.

Data from ClinVar and the ICF Registry. Note: ICF2 is defined by ZBTB24 mutations; CDCA7 mutations cause ICF3.

ZBTB24 loss affects multiple signaling networks:

• • Epigenetic regulation: ZBTB24 is part of a complex with CDCA7 and HELLS, which regulates DNA methylation. Loss of ZBTB24 leads to hypomethylation of centromeric and pericentromeric repeats.
• • Immune signaling: ZBTB24 influences the expression of genes involved in B-cell receptor signaling and T-cell activation.
• • Cell cycle control: Centromeric instability leads to aneuploidy and cell cycle arrest.

Key nodes include DNMT3B, HELLS, and CDCA7. These interactions are critical for maintaining genomic stability.

Organoids derived from patient iPSCs are also being developed to model immune defects. These systems allow for studying disease mechanisms in a more physiologically relevant context.

• • Zebrafish models: ZBTB24 knockout zebrafish show defective lymphopoiesis, recapitulating immune defects.
• • Mouse models: Conditional knockout mice for ZBTB24 are being generated to study tissue-specific effects.
• • Patient-derived xenografts (PDX): Not commonly used due to the rarity of the disease, but iPSC-derived hematopoietic stem cells can be xenografted into immunodeficient mice.

These models are valuable for studying disease progression and testing therapeutic interventions.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise mutations in ZBTB24. These models include:

• • ZBTB24 knockout cell lines: Complete loss of function, mimicking null mutations.
• • ZBTB24 point-mutation knock-in lines: Express specific patient mutations (e.g., R320X) to study genotype-phenotype correlations.
• • ZBTB24 reporter lines: Tagged with GFP or luciferase to monitor expression and localization.

These sequence-verified models are commercially available and accelerate research by providing consistent, reproducible systems. They are essential for functional genomics, drug screening, and target validation.

Gene-edited cell lines are used to validate the function of ZBTB24 and its interacting partners. For example:

• • Knockout of ZBTB24 in K562 cells leads to reduced expression of immune-related genes, confirming its role in immune regulation.
• • Knock-in of a patient-specific mutation (e.g., R320X) allows for studying the impact on protein stability and downstream signaling.

These models help identify novel biomarkers and therapeutic targets.

Isogenic pairs (wild-type vs. ZBTB24 knockout) are used in high-throughput screens to identify compounds that rescue the phenotype. For example:

• • Screening for drugs that restore DNA methylation at centromeric regions.
• • Testing epigenetic modulators, such as DNA methyltransferase inhibitors, for their ability to correct immune defects.

These screens can also identify mechanisms of resistance to existing therapies.

CRISPR-based synthetic lethality screens can identify genes that are essential in ZBTB24-deficient cells but not in wild-type cells. This approach can uncover novel therapeutic vulnerabilities. Additionally, gene-edited cells can be used to identify methylation markers that correlate with disease severity.